# A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

> **NCT03785925** · PHASE2 · COMPLETED · sponsor: **Nektar Therapeutics** · enrollment: 192 (actual)

## Conditions studied

- Urinary Bladder Neoplasm
- Neoplasm Metastasis

## Interventions

- **BIOLOGICAL:** Bempegaldesleukin
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03785925
- **Lead sponsor:** Nektar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-29
- **Primary completion:** 2022-02-09
- **Final completion:** 2022-06-30
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2023-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785925, "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03785925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*